Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Monday, 17 June 2013
MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones
Monday, 10 June 2013
AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio AstraZeneca announced today that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Tuesday, 28 May 2013
AstraZeneca to acquire Omthera Pharmaceuticals including NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialisation of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar